Finny logo
Finny logo
Dibs:
Dibs:
0

Coherus BioSciences (CHRS) earnings: expect 39% EPS growth

1:42 pm ET, 08 May 2019

Coherus BioSciences (CHRS) is announcing earnings on May 09 after the market closes. We combed through analyst estimates to understand what the company revenue and earnings are predicted to look like.

What should you expect from the upcoming earnings?

Revenue for the next quarter is expected to be $42M.

Earnings per share are expected to come in at $-0.45. If this materializes, EPS will grow 39% year-over-year.

How did the stock do last month?

Over the last month, Coherus BioSciences (CHRS) returned +18.52%.

For the latest price and information on Coherus BioSciences, please visit Finstead and ask for "CHRS", "CHRS analysis" or "CHRS news".

Coherus Biosciences (CHRS) stock: will the rally continue?

12:35 pm ET, 19 Jul 2018

Coherus BioSciences, Inc. (CHRS) shares are trading at 18.00, up 21% from two days ago. What's driving CHRS stock price?  What's CHRS stock price forecast, i.e., prediction?

The stock price surge was driven by Coherus Bio's European application for Neulasta biosimilar, which is now under review.  

The company satisfied the Day 180 issues related to its European marketing application seeking approval for Neulasta biosimilar CHS-1701.  The application is now officially under review by the European Medicine Agency, commonly known as the EMA.

Our technical analysis shows that:

  • The stock short-term sentiment (next 30 days) is trending positive;
  • The mid-term sentiment (3-6 months) is positive;
  • The long-term sentiment (9-12 months) is positive.

Over the last month, Coherus BioSciences, Inc. (CHRS) returned +17.38%. 

Coherus BioSciences, Inc. (CHRS) short share of float is 13.49%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock.

For the latest price and information on Coherus BioSciences, Inc., please visit Finstead and search for "CHRS price" or "CHRS news".

Coherus BioSciences, Inc. (CHRS) Stock Guide

Updated at: 2:06 pm ET, 17 Sep 2020

Before we start: if you're looking for CHRS stock price, you can quickly find it out by visiting Finny and typing "CHRS quote". If you're looking for a quick scoop on CHRS stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "CHRS". You'll get all this info in one place. Or you can just type "CHRS news" to get the latest stock news.

Looking to buy or sell Coherus BioSciences, Inc. (CHRS)? Interested in getting the full scoop on CHRS, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this CHRS stock guide, we'll address key questions about CHRS, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are CHRS earnings?
2. What is CHRS stock forecast (i.e., prediction)?
3. CHRS buy or sell? What is CHRS Finny Score?
4. What are the reasons to buy CHRS? Why should I buy CHRS stock?
5. What are the reasons to sell CHRS? Why should I sell CHRS stock?
6. What are CHRS key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are CHRS earnings?

CHRS trailing 12-month earnings per share (EPS) is $2.37.

Analyst Predictions

2. What is CHRS stock forecast (i.e., prediction)?

Based on CHRS analyst price targets, CHRS stock forecast is $30.44 (for a year from now). That means the average analyst price target for CHRS stock is $30.44. The prediction is based on 8 analyst estimates.

The low price target for CHRS is $22.00, while the high price target is $35.00.

CHRS analyst rating is Buy.

Analysis

3. CHRS buy or sell? What is CHRS Finny Score?

#{finnyScore:73}Our quantitative analysis shows 8 reasons to buy and 3 reasons to sell CHRS, resulting in Finny Score of 73.

4. What are the reasons to buy CHRS? Why should I buy CHRS stock?

Here are the reasons to buy CHRS stock:

  • The company expects to see strong sales from one of its drugs, Neulasta biosimilar UDENYCA.
  • The company's key product UDENYCA is 33% cheaper than its main competitor Neulasta. The company feels positive about the product-market fit: UDENYCA meets the needs of providers, payers and patients.
  • CHRS quarterly revenue growth was 62.60%, higher than the industry and sector average revenue growth (0.28% and 0.83%, respectively). See CHRS revenue growth chart.
  • CHRS forward P/E ratio is 14.27, which is low compared to its industry peers’ P/E ratios. See CHRS forward P/E ratio chart.
  • CHRS Price/Sales ratio is 2.74, which is low compared to its industry peers’ P/S ratios. See CHRS forward Price/Sales ratio chart.
  • CHRS PEG ratio (P/E adjusted for growth) is 4.49, which is low compared to its industry peers’ PEG ratios. See CHRS PEG chart.
  • CHRS average analyst rating is Buy. See CHRS analyst rating chart.
  • CHRS average analyst price target ($30.44) is above its current price ($19.11). See CHRS price target chart.
  • CHRS cash to debt ratio is 1.10, higher than the average industry (0.16) and sector (0.16) cash to debt ratio. See CHRS cash to debt chart.
  • CHRS Enterprise Value/Revenue multiple is 2.70, which is low compared to its industry peers’ Enterprise Value/Revenue multiples. See CHRS Enterprise Value/Revenue chart.

5. What are the reasons to sell CHRS? Why should I sell CHRS stock?

Let's look at the reasons to sell CHRS stock (i.e., the bear case):

  • CHRS Price/Book ratio is 6.25, which is high compared to its industry peers’ P/B ratios. See CHRS forward Price/Book ratio chart.
  • CHRS short share of float is 31.10%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See CHRS short share of float chart.
  • CHRS short interest (days to cover the shorts) ratio is 17.26. The stock garners more short interest than the average industry, sector or S&P 500 stock. See CHRS short interest ratio chart.

Key Stats

6. What are CHRS key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for CHRS:

Metrics CHRS
Price $16.57
Average Price Target / Upside $30.22 / 82.38%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 232
Market Cap $1.31B
Forward P/E Ratio 13.54
Price/Book Ratio 2.68
Revenue (TTM) $487.39M
YoY Quarterly Revenue Growth 62.60%
Profit Margin 37.11%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us